Publications

A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice

 30
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice

Tags:

Previous Article

Animal model for antitumor immunity in lung cancer

Next Article

New antibody for cancer treatment?

Related Posts

Histone H3.3 lysine 9 and 27 control repressive chromatin at cryptic enhancers and bivalent promoters

Histone H3.3 lysine 9 and 27 control repressive chromat...

 17

Pain hypersensitivity is dependent on autophagy protein Beclin 1 in males but not females

Pain hypersensitivity is dependent on autophagy protein...

 41

Artificial intelligence-based biomarkers for treatment decisions in oncology

Artificial intelligence-based biomarkers for treatment ...

 26